Context Therapeutics Inc. announced on September 23, 2024, that it has entered into an exclusive worldwide license agreement with BioAtla, Inc. to develop, manufacture, and commercialize BA3362, a Nectin-4 x CD3 T cell engaging (TCE) antibody. This agreement grants Context exclusive rights to the asset, which will now be known as CT-202.
Under the terms of the agreement, BioAtla is eligible to receive up to $133.5 million in aggregate payments, including $15.0 million in upfront and near-term milestones. Additional potential clinical, development, and commercial milestones total $118.5 million, along with tiered royalties on net sales.
Context will assume and fund all development and commercialization activities for CT-202. The company anticipates filing an Investigational New Drug (IND) application for BA3362 in mid-2026, further expanding its pipeline of TCE bispecific antibodies for solid tumors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.